CDK9 and cancer: Given the immense challenge to identify novel therapeutic strategies which could offer treatment alternatives that are significantly more efficacious than current standard-of-care therapies, we treated several cancer cell lines which showed only a partial or low response to their respective first-line treatments (Fig. 1d and Supplementary Fig. 1f) with TRAIL and/or the CDK9 inhibitor.